Alto Neuroscience Files 8-K with Definitive Agreement Update
Ticker: ANRO · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 8-K |
| Filed Date | Feb 3, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $75,000,000, $168 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-update, sec-filing
TL;DR
Alto Neuroscience just filed an 8-K – looks like a big new deal is in the works.
AI Summary
Alto Neuroscience, Inc. filed an 8-K on February 3, 2025, reporting an entry into a material definitive agreement and providing updates on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Mountain View, California.
Why It Matters
This 8-K filing signals a significant development for Alto Neuroscience, potentially involving a new material agreement that could impact its operations and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce significant opportunities or risks, and the lack of specific details in this initial report warrants a medium risk assessment.
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 650 Castro Street, Suite 450, Mountain View, CA 94041 (address) — Principal executive offices
- (650) 200-0412 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by Alto Neuroscience?
The filing indicates an entry into a material definitive agreement, but the specific details of this agreement are not provided in the initial summary of the 8-K.
What information is provided regarding Alto Neuroscience's results of operations and financial condition?
The 8-K states that the company is reporting on its results of operations and financial condition, but specific financial figures or operational details are not elaborated upon in the provided text.
When was this 8-K report filed and what is the earliest event date reported?
The 8-K report was filed on February 3, 2025, and the earliest event reported is also February 3, 2025.
Where are Alto Neuroscience's principal executive offices located?
Alto Neuroscience's principal executive offices are located at 650 Castro Street, Suite 450, Mountain View, CA 94041.
What is Alto Neuroscience's standard industrial classification?
Alto Neuroscience's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Filing Stats: 1,044 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2025-02-03 16:39:05
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ANRO New York S
- $75,000,000 — ng an aggregate offering price of up to $75,000,000. Subject to the terms and conditions
- $168 m — h and cash equivalents of approximately $168 million, as of December 31, 2024. The C
Filing Documents
- d843857d8k.htm (8-K) — 30KB
- 0001193125-25-019318.txt ( ) — 154KB
- anro-20250203.xsd (EX-101.SCH) — 3KB
- anro-20250203_lab.xml (EX-101.LAB) — 18KB
- anro-20250203_pre.xml (EX-101.PRE) — 11KB
- d843857d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits. Exhibit No. Description 10.1 Sales Agreement, dated as of February 3, 2025, by and between the Company and Leerink Partners LLC (incorporated by reference to Exhibit 1.2 of the Company's Registration Statement on Form S-3 filed on February 3, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: February 3, 2025 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer